Novavax, Inc.
https://novavax.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Novavax, Inc.
Sanofi’s $500m COVID-19 Deal Comes Four Years Too Late
But it rescues embattled Novavax.
A Job Well Done: AstraZeneca Bids Adieu To Vaxzevria As Demand Dries Up
The voluntary withdrawal of the license for the UK major's COVID-19 vaccine is due to a surplus of available updated jabs from other companies that target new variants and is not connected to the mis- and disinformation being peddled on the internet and elsewhere on very rare adverse events.
Deal Watch: Bristol Adds To Vaccines ‘Repertoire,’ Takes ‘Scenic’ View Of Cellular Pathways
BMS partners with Repertoire and Scenic, plus deals involving: G1/Pepper, Harmony/Epygenix, Biodexa/Emtora, Regeneron/Mammoth, Vertex/Treefrog and Immedica/KKR/Impilo.
Key Activist Investor Throws Shade At Novavax Over COVID-19 Vaccines
Shah Capital Management said Novavax could tap the estimated 100 million Americans uncomfortable with mRNA vaccines, such as those from Pfizer/BioNTech and Moderna.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
- Vaccines
-
Biotechnology
- Liposomes
- Other Names / Subsidiaries
-
- CPL Biologicals Pvt. Ltd. (Joint Venture with Cadila)
- Isconova AB
- Novavax AB
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice